Showing 5761-5770 of 7139 results for "".
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- Luminora Launches New UPF Sunwear Linehttps://practicaldermatology.com/news/luminora-launches-new-upf-sunwear-line/2458169/Founded by skin cancer surgeon, Dr. Ali Hendi, and his designer wife, Azi Hendi, the Spring/Summer 2017 collection from Luminora launched in May with 12 foundational pieces priced from $60 to $485. Luminora™ is a new
- PFD Patch Improves Laser Tattoo Removal Experiencehttps://practicaldermatology.com/news/pfd-patch-improves-laser-tattoo-removal-experience/2458170/Using a perfluorodecalin (PDF) patch during tattoo removal treatment may make the process quicker, safer and more tolerable, finds a new study in Lasers in Surgery and Medicine (LSM). The study was selected a
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Consumer Reports: One-Third of Tested Sunscreens Delivered Less Than Half of Labeled SPF Protectionhttps://practicaldermatology.com/news/consumer-reports-one-third-of-tested-sunscreens-delivered-less-than-half-of-labeled-spf-protection/2458180/For the fifth year in a row, Consumer Reports’ testing has shown that some sunscreens failed to provide the level of protection promised on the package. Of the more than 60 lotions,&nb
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- CVS Pharmacy's New Long Live Skin Campaign Aims to Increase Awareness of Skin Healthhttps://practicaldermatology.com/news/cvs-pharmacys-new-long-live-skin-campaign-aims-to-increase-awareness-of-skin-health/2458183/CVS Pharmacy, the retail division of CVS Health, is rolling out a new multi-platform Long Live Skin campaign to increase awareness about skin health, sun safety and proper skincare. The Long Live Skin Campaign kicks off today online&nbs
- RCM Imaging of Skin Granted Reimbursement Codes by CMS; Wider Adoption Likelyhttps://practicaldermatology.com/news/rcm-imaging-of-skin-granted-reimbursement-codes-by-cms/2458187/After more than two decades of effort, reflectance confocal microscopy (RCM) imaging of skin has been granted reimbursement codes by the US Centers for Medicare and Medicaid Services. A report in Lasers in Sur
- Unilever Ventures Invests in Nutrafolhttps://practicaldermatology.com/news/unilever-ventures-invests-in-nutrafol/2458189/Unilever Ventures, the venture-capital and private-equity arm of consumer packaged goods conglomerate, has emerged as lead investor at the conclusion of series A financing round for Nutrafol®. Investment platform CircleUp made an initial introduction to